Cero Therapeutics signs SRX Global secured note for up to $11.67 million

Cero Therapeutics completed a secured financing with SRX Global on Aug. 27, 2026, issuing a Consolidated Senior Secured Promissory Note.

• The note consolidates USD 5.67 million of previously outstanding debt held by SRX and debt originally held by Keystone Capital Partners.
• The facility allows up to USD 6 million of additional SRX advances, taking the maximum aggregate loan amount to USD 11.67 million.
• SRX funded an initial USD 775,665 advance; USD 50,000 was withheld to cover SRX legal expenses.
• The note bears 10% interest, rising to up to 24.99% on default; it matures Oct. 15, 2026, with up to four 30-day extensions.